

# Explore toxicities associated with compounds and targets

## Cortellis Drug Discovery Intelligence


There are 3 ways of exploring toxicity data in the platform:

- Via **Experimental pharmacology** for toxicities reported in preclinical models
- Via **Clinical studies** for case studies where adverse events have been reported in humans
- Via **Biomarkers** that can predict or monitor the toxic effects of your drugs of interest – Requires a separate subscription to access Biomarkers Module


  
565 Safety Alerts

\*In addition, subscribers to **OFF-X** can access further drug safety data by clicking on **Safety Alerts** in **Drug & Biologics** and **Genes & Targets** records.

To start with, **Quick Search** for your drug/drug class/target of interest. Eg MoA = **PARP inhibitors**.




From the **All-Related Content**, page navigates to the area of interest.



All results for "NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibit..."

2029 Drugs & Biologics	58 Genes & Targets	113 Organic Synthesis
16260 Experimental Pharmacology	1862 Experimental Models	9437 Pharmacokinetics
8649 Clinical Studies	277 Organizations	19111 Literature
1248 Patents	20 Disease Briefings	4781 Biomarkers
		13141 Uses

- Go to **Experimental Pharmacology** – Click on **Apply filters > Toxicity** to view the list of toxicity-related **Experimental Activities** are shown in your results. **Select All** to refine your results and view the details.



**Apply Filters** X

Experimental Activity >

Pharmacological Activity >

Target >

Condition >

**Toxicity (15)** >

Activity/Effect >

System >

Search

Select all / Clear all

- ☒ Cytotoxicity (298)
- ☒ Death (40)
- ☒ Hepatotoxicity (20)
- ☒ Neurotoxicity (18)
- ☒ Cancer, breast (9)
- ☒ Genotoxicity (6)
- ☒ Leukemia, promyelocytic acute (6)
- ☒ Nephrotoxicity (3)
- ☒ Phototoxicity (3)

2. Go to **Clinical studies** – Click on **Apply filters > Condition** and refine by **Adverse Events** and **Drug toxicities and Adverse Events**. Find details on the reported adverse events in the **Conclusions/Objective** section within the records.

Clinical Studies Record

General Information

Study Name  
Neutropenic enteritis/cutaneous hyperpigmentation due to pemetrexed

Study Design  
Case report

Population  
Male Caucasian patient aged 77 y with malignant pleural mesothelioma

Population Number  
1

Intervention  
Carboplatin, 225 mg/m2 + Pemetrexed, 500 mg/m2 1x/4 wks x 3 cycles --> [if severe abdominal pain] Pemetrexed, 420 mg/m2

Intervention Type  
Drug therapy

Drugs  

Carboplatin

Pemetrexed disodium

Conclusions/Objectives  
Treatment with pemetrexed resulted in neutropenic enteritis and severe cutaneous hyperpigmentation in a male Caucasian patient with malignant pleural mesothelioma

Condition  

Adverse Events
Gastroenteritis
Hyperpigmentation, skin
Mesothelioma, malignant
Show 1 more

Apply Filters

adver

Surgical and Medical Procedures (301)

Drug toxicities and Adverse Events (177)

Adverse Events (150)

Study Design

Phase

Condition (5)

Intervention Type

3. Go to **Biomarker Uses** – Click on **Apply filters > Role** and refine by **Predicting treatment toxicity**, **Monitoring treatment toxicity**, and **Toxicity profiling**.

Apply Filters

tox

Biomarker Type

Highest Validity

Combination Biomarker

**Biomarker Uses**

**(3)**

Condition

Population

**Role**

**(3)**

☒ Predicting Treatment Toxicity (317)

☒ Monitoring Treatment Toxicity (76)

☒ Toxicity Profiling (70)

Biomarkers

**Biomarker Uses**

Biomarker Kits

▼ Apply Filters

Sorted by relevance

Biomarker Uses - Role 3

<input type="checkbox"/> Biomarker Name	Indication	Population
<input type="checkbox"/> Glucose	<input checked="" type="checkbox"/> Tx Hypercalcemia (grade 3)	Cancer
<input type="checkbox"/> Aspartate aminotransferase	<input checked="" type="checkbox"/> Tx Aspartate aminotransferase elevation (grade 2)	Cancer
<input type="checkbox"/> Glucose	<input checked="" type="checkbox"/> Tx Hypercalcemia (grade 2)	Cancer

the **Tx** symbol in front of the **Indication** column shows which adverse event was detected by the

The condition under the **Population** column shows the underlying condition that was being treated

For more information contact Customer Service at **LS Product Support.**